Establishment Labs Announces Initial Data Regardin

NEW YORK, July 10, 2017 (GLOBE NEWSWIRE) -- Establishment Labs, a global medical technology company focused on aesthetic technologies with a strong emphasis on product development and innovation, today announced that Professor Robert Langer, Chairman of its Scientific Advisory Board, presented initial data highlighting the benefits of the company’s proprietary SilkSurface® technology at the recent, 13 ^th Annual Beauty Through Science (BTS) Congress held in Stockholm, Sweden on June 1-3, 2017. BTS is considered one of the premier events worldwide in the field of plastic surgery.

“At Beauty Through Science, we look to bring the highest levels of science to plastic surgery, and we are honored that Professor Robert Langer accepted our invitation as keynote speaker,” said Dr. Per Héden, BTS President. “The latest advances in material sciences and biomedical engineering need to be incorporated into everything we do as plastic surgeons, and his lecture spoke to the rigorous scientific approach we must demand from ourselves and from industry. His commitment to understanding the biocompatibility of implant surfaces is of the utmost importance to our field.”

“Published studies determine macrophages to be the sole immune population necessary for inflammation and fibrosis. In our pilot study, we were able to prove that, compared to a smooth surface control, Establishment Labs’ SilkSurface decreases fibrosis-dependent-innate immune macrophages,” said Professor Langer. “We will continue to work in collaboration with the scientists at Establishment Labs to further evaluate the fibrotic response mechanism in breast implant surfaces,” he added.

Professor Langer’s discoveries have created meaningful advancements in the fields of engineering, science, and medicine. In addition to serving on Establishment Labs’ Scientific Advisory Board, Professor Langer is one of 13 designated Institute Professors at MIT, the highest honor awarded to a faculty member. Professor Langer also holds over 1,250 issued and pending patents which have been licensed or sublicensed to over 350 companies. Professor Langer has also previously served as a Chairman of the Federal Drug Administration’s Science Board. Professor Langer’s full bio can be referenced at http://web.mit.edu/langerlab/langer.html .

About Establishment Labs  Establishment Labs is a global, privately held, medical technology company with a strong emphasis on innovation that designs, develops, manufactures and markets an innovative product portfolio. Its CE-marked Motiva Implants® line of silicone breast implants ( http://www.motivaimplants.com ) utilizes ultra-high purity medical-grade silicone and is subject to the strictest quality assurance testing throughout the manufacturing process. Motiva Implants® are sold in more than 60 countries worldwide. Puregraft®'s FDA cleared and CE-Marked technology provides plastic surgeons with purified fat for reinjection on the sterile field and is used in hospitals and clinics around the world. Divina® is a proprietary 3D imaging technology for full integration in consultation and surgical planning of unique solutions for breast aesthetics and reconstruction.  All manufacturing facilities are fully compliant with both FDA and ISO applicable standards.

Contact Lynn Pieper Lewis or Leigh Salvo Gilmartin Group (415) 937-5404 leigh@gilmartinir.com